Neurocrine Biosciences (NBIX) Change in Receivables (2010 - 2026)

Neurocrine Biosciences' Change in Receivables history runs 17 years deep, the most recent figure standing at $81.4 million for Q1 2026.

• Quarterly Change in Receivables rose 120.6% year-over-year to $81.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $255.0 million (up 289.91% YoY) and the FY2025 annual result came in at $210.5 million, up 428.89% from the prior year.
• Change in Receivables was $81.4 million for Q1 2026 at Neurocrine Biosciences, up from -$38.4 million in the prior quarter.
• Across five years, Change in Receivables topped out at $132.3 million in Q3 2025 and bottomed at -$38.4 million in Q4 2025.
• A 5-year average of $34.3 million and a median of $22.2 million in 2022 frame the typical range for Change in Receivables.
• Annual changes were most pronounced in 2022 — Change in Receivables surged 938.71% — and 2025, when it tumbled 1820.0%.
• Neurocrine Biosciences' Change in Receivables stood at $46.5 million in 2022, then sank by 53.98% to $21.4 million in 2023, then sank by 109.35% to -$2.0 million in 2024, then tumbled by 1820.0% to -$38.4 million in 2025, then jumped by 311.98% to $81.4 million in 2026.
• Business Quant data shows NBIX's Change in Receivables at $81.4 million in Q1 2026, -$38.4 million in Q4 2025, and $132.3 million in Q3 2025.